Veterans’ Groups Demand Access to Psychedelics, Marijuana Through VA

March 17, 2021 13:34:47

Leaders of various military veterans’ organizations have issued a message to congressional legislators stating that federal psychedelics and cannabis laws were out of date and needed to be reformed. This, they said, would provide service members with alternative treatment options for conditions such as PTSD.

Additionally, three veterans service organizations presented written testimonies during the House and Senate Veterans Affairs Committees hearings recently. The testimonies supported a change in policy that would allow more research to be conducted on medical marijuana and broaden access to medical marijuana, with another arguing that loosening restrictions would allow veterans to use psychedelics as part of their mental health treatment.

In its written testimony, the Minority Veterans of America (“MVA”) stated that research on marijuana had shown its efficacy in lowering opioid use and opioid-related deaths as well as treating substance use disorders and post-traumatic stress disorder in veteran populations. The group added that while more research was required, research on psychedelics had also shown its effectiveness in treating both PTSD and substance use disorders.

The MVA also noted that while the Veterans Affairs department had allowed the use of ketamine-based therapies on a case-by-case basis to manage severe depression, studies had shown that other psychedelics also demonstrated potential in the treatment of conditions that often plagued veterans. The group added that legislators should therefore consider permitting marijuana and psychedelics to be added to the psychopharmacological treatments profile.

Iraq and Afghanistan Veterans of America (“IAVA”) stated in its testimony that support for the use of medical marijuana in the veteran population had grown, noting that medical marijuana could create thousands of jobs for veterans across the country while also providing relief to millions of veterans.

The group argued that the classification of marijuana under the Controlled Substances Act as a Schedule 1 drug not only impeded the progression of research on the plant but also made the scientific process burdensome and complicated. IAVA added that it would continue to advocate for more research to be conducted on the medical potential of cannabis.

Concurrently, Disabled American Veterans (“DAV”) declared in its statement that it supported Veterans Affairs research into the effectiveness of marijuana for the treatment of veterans.

Finally, the national president of the Paralyzed Veterans of America, David Zurfluh, stated that the body fully supported research on medical cannabis, noting that marijuana was used to manage pain by military veterans.

The testimonies given by the three veterans’ groups aligned greatly with prior hearings before the joint Senate and House panels.

As veterans’ groups campaign for law reform with regard to psychedelics and marijuana, companies such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are hard at work advancing psychedelic medicine. This particular company has acquired exclusive global rights to technology geared at delivering psychedelic medicines orally through a film.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.